Anjali S. Advani, MD

Leukemia Program, Department of Hematology and Medical Oncology
Taussig Cancer Institute, Cleveland Clinic
10201 Carnegie Avenue
Desk CA60
Cleveland, OH
USA 44195
Email: advania@ccf.org
Papers:
33 Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia
211 Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies
331 Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative and Subgroup Analyses
371 Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States
712 Pharmacist Interventions on Outpatient Leukemia Patients Improve Safety
900 Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?
1389 Clinical Outcomes for Patients with Myeloid Malignancies Harboring IDH1/2mutations after Intensive Chemotherapy
1527 Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia
1797 Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
2075 Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
2270 TP53 Mutations in Myeloid Neoplasm Patients with and without Significant Personal and Family History of Cancer
2298 Survival Outcomes of Patients with Therapy-Related Acute Myeloid Leukemia in the United States
2590 Clinical and Molecular Heterogeneity of Moderate Aplastic Anemia
2699 Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials
3084 Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential
3869 Impact of Eltrombopag on Clonal Evolution in Refractory Aplastic Anemia
4031 Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study
4353 Distinct Implications of TP53 Hits for Patients with Treatment-Related MDS and AML
4603 Risk Factors for Early Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia
4768 Adolescent and Young Adult (AYA) Hematopoietic Cell Transplantation (HCT) Recipients Have Similar Quality of Life (QoL) Compared to Older Adults in the First Year Post-Transplantation
4805 Risk of Venous Thromboembolism in Acute Leukemias: A Meta-Analysis
4806 Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay